Figure Legends
FIGURE 1. Histological and immunohistochemical features of our patient with OMS-NB.
(A) Multiple lymphoid follicles (arrowhead) are present in the neuroblastoma tissue (hematoxylin and eosin staining; x4). (B) High magnification image of lymphoid follicle in neuroblastoma tissue (hematoxylin and eosin staining; x200). (C) Lymphoid follicle stained with CD3 monoclonal antibody. Sparse CD3-positive cells are visible in the germinal center, follicular mantle and interstitium (peroxidase staining; x100). (D) Lymphoid follicle stained with CD20 antibody. CD20-positive cells are concentrated in the germinal center and follicular mantle (peroxidase staining; x100). (E) Lymphoid follicle stained with CD21 monoclonal antibody. CD21-positive cells are concentrated in the germinal center (peroxidase staining; x100). OMS-NB, Opsoclonus-myoclonus syndrome associated with neuroblastoma.
FIGURE 2. DEX pulse and IVIg treatment effect on OMS Rating Scales and CSF data.
Severity of OMS symptoms was evaluated using OMS Rating Scales, as previously reported. [8] The OMS Rating Scales evaluate six symptoms: stance, gait, arm function, opsoclonus, mood/behavior and speech. Each symptom is scored from 0 to 3 for increasing severity, then the total score is evaluated. Our patient was too young to be speaking, therefore we evaluated five symptoms (excluding speech) for the OMS Rating Scales score. B-cell ratio in CSF means the ratio of B cells to total cells in CSF. DEX, dexamethasone; IVIg, intravenous immunoglobulin; OMS, Opsoclonus-myoclonus syndrome; CSF, cerebrospinal fluid.